Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $29.29

Oculis Holding AG (NASDAQ:OCS) has been given an average rating of “Buy” by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $29.29.

OCS has been the topic of several recent research reports. Robert W. Baird cut their target price on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Oculis in a report on Tuesday, March 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Oculis in a research note on Thursday, February 29th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. HRT Financial LP purchased a new stake in Oculis during the first quarter worth approximately $178,000. Barclays PLC purchased a new stake in shares of Oculis during the 2nd quarter worth approximately $44,000. Ergoteles LLC purchased a new position in shares of Oculis in the 2nd quarter valued at $247,000. Wolverine Asset Management LLC acquired a new stake in Oculis during the 3rd quarter worth $77,000. Finally, Compagnie Lombard Odier SCmA lifted its position in Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after acquiring an additional 30,750 shares during the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Trading Up 2.7 %

NASDAQ:OCS opened at $11.99 on Tuesday. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $12.00 and a 200 day moving average price of $11.18. Oculis has a fifty-two week low of $8.43 and a fifty-two week high of $14.50.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. The firm had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.28 million. As a group, equities analysts forecast that Oculis will post -1.75 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.